{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

Ataxia and tremor issue of MS in focus out soon!

Issue 13 of our biannual magazine will look in detail at the symptoms of tremor and ataxia.

read more

Only 15 weeks to go until World MS Day!

Has your MS society signed up to participate in the first ever World MS Day on Wednesday 27 May 2009?

read more

back to top

Profile of the Month : January 2010

Adrijana Nikolić

Country: Montenegro
Connection with MS: Mother has MS
Profession: Executive Director, Montenegro MS Association (Udruženje Multiple Skleroze Crne Gore-Podgorica)
Age: 38

After my personal experience with MS I wanted to help other people in a similar situation so I decided to set up a national MS society in Montenegro.

read more

back to top

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

This preliminary study investigated the safety and efficacy of stem cell transplantation in people with relapsing-remitting MS who did not respond to beta-interferon. It was found that it stopped progression and improved disability. However, some important side effects were reported. Further and larger studies are needed to confirm these results.

authors: Burt RK, Loh Y, Cohen B, Stefosky D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH

source: Lancet Neurol. 2009 Jan 29. [Epub ahead of print]

read more

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

Treatment with natalizumab, a new medication for aggressive relapsing-remitting MS, can uncommonly induce a progressive multifocal leukoencephalopathy (PML), which is a very serious condition. The authors found that plasma exchange can clear natalizumab from the blood, and concluded that it may be a potential treatment in cases of PML.

authors: Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, Tucky B, Lynn F, Jurgensen S, Woodworth J, Goelz S, Duda PW, Panzara MA, Ransohoff RM, Fox RJ

source: Neurology. 2009 Feb 3;72(5):402-9

read more

Immunoglobulins and complement in postmortem multiple sclerosis tissue

The authors compared the inflammation in the brain of people with MS to that occurring in other neurological conditions. They found a specific pattern in MS lesions which may be significant in the pathogenesis of MS.

authors: Barnett MH, Parratt JD, Cho ES, Prineas JW

source: Ann Neurol. 2009 Feb 4;65(1):32-46. [Epub ahead of print]

read more

Direct visualization of remyelination in multiple sclerosis using T2-weighted high-field MRI

This article reports that MRI scans obtained using a very high field magnet (9.4 T) can detect remyelination, suggesting that high-field MRI can be useful in studying people with MS.

authors: Schmierer K, Parkes HG, So PW

source: Neurology. 2009 Feb 3;72(5):472

read more

back to top

"Yes we care … let us get together!" MS Society India organise human chain to raise awareness

source: MS Society of India

More than 100 people held hands to raise awareness for MS on 1 February 2009 in Pune, India.

read more

Genetic study shows direct link between vitamin D and MS susceptibility 'gene'

source: MS Society of Canada and UK MS Society

Scientists have found evidence that a direct interaction between vitamin D and a common genetic variant alters the risk of developing MS.

read more

Spanish "Get wet for MS" campaign wins award

source: Federación Española para la Lucha contra la Esclerosis Múltiple

The Spanish MS Federation, Federación Española para la Lucha contra la Esclerosis Múltiple (FELEM), have won a campaigning award from the Medical Economics magazine.

read more

Copaxone® is approved for treatment of patients with a first clinical event suggestive of MS

source: MS Trust UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an expanded label for COPAXONE® (glatiramer acetate injection) to include the treatment of patients with clinical isolated syndrome (CIS) suggestive of multiple sclerosis (MS).

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.